Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Invested Capital (2020 - 2022)

Historic Invested Capital for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $663.2 million.

  • Atea Pharmaceuticals' Invested Capital rose 1405.71% to $663.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $663.2 million, marking a year-over-year increase of 1405.71%. This contributed to the annual value of $710.1 million for FY2021, which is 2962.32% up from last year.
  • Atea Pharmaceuticals' Invested Capital amounted to $663.2 million in Q3 2022, which was up 1405.71% from $660.5 million recorded in Q2 2022.
  • In the past 5 years, Atea Pharmaceuticals' Invested Capital registered a high of $710.1 million during Q4 2021, and its lowest value of -$76.5 million during Q3 2020.
  • Its 3-year average for Invested Capital is $439.5 million, with a median of $586.3 million in 2021.
  • Per our database at Business Quant, Atea Pharmaceuticals' Invested Capital skyrocketed by 119847.85% in 2021 and then skyrocketed by 1047.0% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Invested Capital stood at $547.8 million in 2020, then increased by 29.62% to $710.1 million in 2021, then decreased by 6.6% to $663.2 million in 2022.
  • Its Invested Capital was $663.2 million in Q3 2022, compared to $660.5 million in Q2 2022 and $679.9 million in Q1 2022.